Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.

ABSTRACT:

Background

The effectiveness and safety of pyrotinib have been substantiated in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC). However, the role of pyrotinib as a single HER2 blockade in neoadjuvant setting among BC patients has not been studied. The objective of this study was to evaluate the efficacy and tolerability of pyrotinib plus taxanes as a novel neoadjuvant regimen in patients with HER2-positive early or locally advanced BC.

Methods

In this single-arm exploratory phase II trial, patients with treatment-naïve HER2-positive BC (stage IIA-IIIC) received pyrotinib 400 mg once daily and taxanes [docetaxel 75 mg/m² or nanoparticle albumin-bound (nab)-paclitaxel 260 mg/m² every 3 weeks, or paclitaxel 80 mg/m

SUBMITTER: Ye G 

PROVIDER: S-EPMC11002487 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature